Since mutations in SLC34A2 which reduce phosphate transport are linked to lung disease [19], [20], [21], we speculate that any SNPs which alter SLC34A2 activity might indirectly affect F508del-CFTR function and potentially impact the outcome of CFTR corrector therapies. Here, CFTR is linked to lung disorder.